The 4th edition of the Kisaco Research international Phage Futures USA will be held in Boston, USA from Wednesday 16th November till Thursday 17th November 2022.
This year, for the first time ever, we’ll be co-located with Microbiome Connect: the USA, allowing you to make meaningful business connections that can streamline your research with 300+ pharma, biotech, investors, and leading solution providers.
What is the 4th Phage Futures USA and Why attend?
Phage therapies have shown promise in compassionate use, but the limited success of double-blind randomized, controlled trials has slowed progression through the clinic.
The 4th edition of Phage Futures USA will present the latest techniques progressing phage technologies into commercially viable products that will improve human health worldwide.
Alongside in-depth case study presentations, join the conversation through interactive panel discussions on key challenges within the space – including attracting public & private support to efficiently finance phage-based therapeutics, evaluating approaches to phage sensitivity testing, and improving clinical trial design for efficacious outcomes.
Join the conversation if you are responsible for; R&D, Innovation, and Regulation, Bioprocessing and Manufacturing, Business Development, and Commercialization.
Who will be at the 4th Phage Futures USA?
Over 20 phage-specific speakers amongst 170+ attendees from a diversity of fields will be attending.
The summit will bring together individuals from all parts of the value chain including; academia, biotech, pharma, regulatory and governments, service providers, and clinicians.
Agenda for the 4th Phage Futures USA 2022
Wednesday 16th November 2022
Anna Jacobs Biologist at BARDA, and Joe Campbell Research Resources Project Office at NIH – Attracting Public and Private Support to Efficiently Finance Phage-BAsed Therapeutics
TBA Senior representative at Locus Biosciences – Advancing CRISPR-Enhanced Phage Therapy Through Clinical Trials
Shawna Mccallin Clinical Coordinator at Balgrist University Hospital, Jen Schwartz Vice President Clinical Development at Intralytix, and Cara Fiore Senior Regulatory Reviewer & Microbiologist at FDA – Improving Clinical Trial Design for Efficacious Outcomes
Nancy Tawil Chief Scientific Officer at PhageLux – Strategies for the Prolonged Transdermal Delivery of Bacteriophage for the Prevention and Treatment of Infected Wounds
TBA – Developing Phage-Based Vaccines to Tackle Multiple Oncology Indications
David Pride Associate Adjunct Professor at UC San Diego – Progression of Virome Studies and Systems Biology for Understanding the Microbiome
TBA Senior Representative at Felix Biotechnologies – Programmable Therapies to Protect Against Antimicrobial Resistance
Bob Blasdel Research Director at Vesale Pharma – Evaluating Approaches to Phage Sensitivity Testing
Cindy Lefevre Director of R&D at Pherecydes – Phagogram – AST/IVD for Phage Therapy in Clinical Studies
Thursday 17th November 2022
Peter Beyer Senior Advisor at WHO – Regulatory standpoint on the progressive routes of phage application
Ella Balasa Patient Advocate & Consultant – A Patient Perspective on the Use of Phage Therapies
Tobi Nagel Founder & President of Phages for Global Health – Considerations on Acceleration of Phage Products into Western Society
Mzia Kutateladze Director at Eliava Institute – Compassionate to Commercial: Accelerating Phage Products into the Mainstream
Michele Wales Chief Legal Officer at Adaptive Phage Therapeutics – The Patenting of Phage: Exploring Phage Therapy as a Future Commercial Entity
Cara Fiore Senior Regulatory Reviewer & Microbiologist at FDA – Regulatory Considerations for Development of Phage Therapeutics
Danish Malik Senior Lecturer at Loughborough University – Formulation and Manufacturing Challenges & Opportunities for the Development of Phage Therapy Products
TBA – Building GMP manufacturing plants to meet pharmaceutical demand
Mikeljon Nikolich Principal Investigator at Walter Reed Army Institute of Research – Developing Phage Therapeutics for Military Applications
Mimi Yen CEO at Phage Pro – Phages For All: Using Cholera Prevention to Establish Phage Infrastructure In Resource-Limited Settings
View past events by Kisaco Research